The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
Daily Summary: Hawkish Fed fails to scare the markets (17.09.2026)
Nasdaq 100 Up 1.7%
US Open: Nasdaq, gold and silver surge following... an interest rate hike (17.09.2026)
JB Hunt shares down 13% 📉 US transportation stocks have problems?